These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29534103)

  • 1. Prevalence and correlates of persistent intracellular HIV transcription in individuals on efavirenz versus atazanavir-based regimens: A prospective cohort study.
    Pilalas D; Skoura L; Margariti A; Chatzopoulou F; Chatzidimitriou D; Tsachouridou O; Zebekakis P; Metallidis S; Papaioannou M
    PLoS One; 2018; 13(3):e0194262. PubMed ID: 29534103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir-boosted protease inhibitor-based versus a nonnucleoside reverse transcriptase inhibitor-based first-line regimen.
    Jarrin I; Hernández-Novoa B; Alejos B; Santos I; Lopez-Aldeguer J; Riera M; Gutiérrez F; Rubio R; Antela A; Blanco JR; Moreno S;
    HIV Med; 2014 Oct; 15(9):547-56. PubMed ID: 24655804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P-glycoprotein (ABCB1) activity decreases raltegravir disposition in primary CD4+P-gphigh cells and correlates with HIV-1 viral load.
    Minuesa G; Arimany-Nardi C; Erkizia I; Cedeño S; Moltó J; Clotet B; Pastor-Anglada M; Martinez-Picado J
    J Antimicrob Chemother; 2016 Oct; 71(10):2782-92. PubMed ID: 27334660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression.
    Huang WC; Huang CK; Huang SH; Lin SW; Ou ST; Chen YT; Chen YW; Chang SY; Liu WC; Sun HY; Hung CC
    J Microbiol Immunol Infect; 2021 Oct; 54(5):944-951. PubMed ID: 32675042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study.
    Shamu T; Egger M; Mudzviti T; Chimbetete C; Manasa J; Anderegg N
    PLoS One; 2024; 19(2):e0293162. PubMed ID: 38394297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients.
    Edén A; Andersson LM; Andersson O; Flamholc L; Josephson F; Nilsson S; Ormaasen V; Svedhem V; Säll C; Sönnerborg A; Tunbäck P; Gisslén M
    AIDS Res Hum Retroviruses; 2010 May; 26(5):533-40. PubMed ID: 20455766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice.
    Gantner P; Bani-Sadr F; Garraffo R; Roger PM; Treger M; Jovelin T; Pugliese P; Rey D;
    PLoS One; 2016; 11(10):e0164240. PubMed ID: 27798641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efavirenz but Not Atazanavir/Ritonavir Significantly Reduces Atovaquone Concentrations in HIV-Infected Subjects.
    Calderón MM; Penzak SR; Pau AK; Kumar P; McManus M; Alfaro RM; Kovacs JA
    Clin Infect Dis; 2016 Apr; 62(8):1036-1042. PubMed ID: 26797214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous plasma and genital pharmacokinetics and pharmacodynamics of atazanavir and efavirenz in HIV-infected women starting therapy.
    Neely M; Louie S; Xu J; Anthony P; Thuvamontolrat K; Mordwinkin N; Kovacs A
    J Clin Pharmacol; 2015 Jul; 55(7):798-808. PubMed ID: 25683232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors involved in continuance of atazanavir-based regimens: Results from a cohort of HIV1-positive patients.
    Giacomelli A; Oreni L; Franzetti M; Di Cristo V; Colella E; Ridolfo AL; Galli M; Rusconi S
    Antiviral Res; 2016 May; 129():52-57. PubMed ID: 26902109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study.
    Xu L; Peng W; Song X; Li Y; Han Y; Zhu T; Fu Q; Du X; Cao W; Li T
    BMC Infect Dis; 2021 Jan; 21(1):112. PubMed ID: 33485301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials.
    Naicker N; Naidoo A; Werner L; Garrett N; Majola N; Asari V; Baxter C; Grobler A; Karim QA; Karim SSA
    Antivir Ther; 2017; 22(4):287-293. PubMed ID: 27835613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial.
    Firnhaber C; Smeaton LM; Grinsztejn B; Lalloo U; Faesen S; Samaneka W; Infante R; Rana A; Kumarasamy N; Hakim J; Campbell TB
    HIV Clin Trials; 2015; 16(3):89-99. PubMed ID: 25979186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and predictors of glucose metabolism disorders among People Living with HIV on combination antiretroviral therapy.
    Tadesse WT; Adankie BT; Shibeshi W; Amogne W; Aklillu E; Engidawork E
    PLoS One; 2022; 17(1):e0262604. PubMed ID: 35045105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virologic and immunologic responses in treatment-naive patients to ritonavir-boosted atazanavir or efavirenz with a common backbone.
    Wang Q; Young J; Bernasconi E; Vernazza P; Calmy A; Cavassini M; Furrer H; Fehr J; Bucher HC; Battegay M;
    HIV Clin Trials; 2014; 15(3):92-103. PubMed ID: 24947533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship Between Genital Drug Concentrations and Cervical Cellular Immune Activation and Reconstitution in HIV-1-Infected Women on a Raltegravir Versus a Boosted Atazanavir Regimen.
    Meditz AL; Palmer C; Predhomme J; Searls K; Kerr B; Seifert S; Caraway P; Gardner EM; MaWhinney S; Anderson PL
    AIDS Res Hum Retroviruses; 2015 Oct; 31(10):1015-22. PubMed ID: 26059647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
    Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
    J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
    Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
    AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir- vs. efavirenz-based antiretroviral therapy.
    Estrada V; Monge S; Gómez-Garre MD; Sobrino P; Masiá M; Berenguer J; Portilla J; Viladés C; Martínez E; Blanco JR;
    HIV Med; 2016 Oct; 17(9):653-61. PubMed ID: 26935006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efavirenz outperforms boosted atazanavir among treatment-naive HIV-1-infected persons in routine clinical care.
    Taniguchi T; Grubb JR; Nurutdinova D; Önen NF; Shacham E; Donovan M; Overton ET
    J Int Assoc Provid AIDS Care; 2013; 12(2):138-41. PubMed ID: 23269514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.